An antidote to stop Pradaxa bleeding may prove to be an effective way of preventing patients from suffering from potentially deadly Pradaxa side effects.

The drug is currently undergoing clinical trials. Boehringer Ingelheim may be the first drug manufacturer to create an antidote for a drug in the new class of blood thinning medications.

About Pradaxa

Pradaxa was the first drug created in a new class of anticoagulants that was created to be an alternative to warfarin. Warfarin was the previously leading anticoagulant that had been used for decades. It requires the patient to undergo blood testing and to follow a strict diet. Pradaxa has no such limitations. It was marketed as a drug that was more user friendly.

However, if a warfarin patient suffers from internal bleeding side effects, there is an antidote that can be administered. If a patient experiences Pradaxa bleeding, there is no approved antidote that can be given. This has resulted in countless individuals suffering from uncontrolled Pradaxa side effects. Many patients have died from Pradaxa bleeding.

Boehringer Ingelheim has allegedly failed to adequately warn about Pradaxa bleeding or the fact that there is no antidote. As a result of these unwarned side effects, many patients have filed Pradaxa internal bleeding lawsuits against Boehringer Ingelheim. 

Pradaxa has only been on the market since 2010, but already over 4,000 Pradaxa internal bleeding lawsuits have been filed. A $650 million settlement has already been paid to resolve a large number of Pradaxa internal bleeding lawsuits, but patients have continued to file lawsuits about Pradaxa bleeding.

Pradaxa Antidote

Boehinger Ingelheim may be the first drug manufacturer to create an antidote to solve the internal bleeding side effects that thousands of users of this new class of drug have experienced.

The blood thinners Xarelto and Eliquis have also been subjected to internal bleeding lawsuits. New drug Savaysa was recently approved, but it has been suggested that it to will carry serious bleeding risks.

The Pradaxa antidote is currently being tested in a phase III study. Over 300 patients will be involved. The results of the study so far were presented at the International Society of Thrombosis and Haemostasis 2015 Congress  and published in the New England Journal of Medicine.

The drug is called idarucizumab, and so far, researchers have found that it has a 88 percent to 98 percent chance of success in patients who are suffering from Pradaxa bleeding. While there were 18 deaths related to Pradaxa side effects, the antidote did work well and quickly on many patients.

It has been suggested that the first drug manufacturer to create an antidote for internal bleeding side effects will have a considerable lead over other drug manufacturers who created these newer anticoagulants.